ECSP045368A - "antagonistas de los receptores de trombina" - Google Patents

"antagonistas de los receptores de trombina"

Info

Publication number
ECSP045368A
ECSP045368A EC2004005368A ECSP045368A ECSP045368A EC SP045368 A ECSP045368 A EC SP045368A EC 2004005368 A EC2004005368 A EC 2004005368A EC SP045368 A ECSP045368 A EC SP045368A EC SP045368 A ECSP045368 A EC SP045368A
Authority
EC
Ecuador
Prior art keywords
optionally substituted
cycloalkyl
bond
ring
thrombine
Prior art date
Application number
EC2004005368A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045368(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ECSP045368A publication Critical patent/ECSP045368A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen tricíclicos sustituidos con heterocíclicos de la fórmulas su sal farmacéuticamente aceptable, en donde la línea punteada representa un enlace simple opcional; _____ - - - - - representa un enlace doble opcional; n es 0-2; Q es cicloalquilo, opcionalmente sustituido por R13 y R14; R13 y R14 se seleccionan independientemente entre alqluilo(C1-C6),cicloalquilo(C3-C8), -OH, alcoxi(C1-C6), R27 -arilalquilo(C1-C6), heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, halógeno y haloalquilo; ó R13 y R14 forman en conjunto un anillo espirocíclico ó un anillo heterospirocíclico de 3-6 átomos; Het es un grupo heteroarilo opcionalmente sustituido mono- ó bicíclico; y B es un enlace, alquileno, ó alquenileno ó alquinileno opcionalmente sustituido, en donde los sustituyentes remanentes son como se definieron en la memoria descriptiva, como así también composiciones farmacéuticas que los contienen y un método para el tratamiento de enfermedades asociadas con trombosis, aterosclerosis, restenosis, hipertensión, angina pectoris, arritmia, insuficiencia cardiaca y cáncer administrando dichos compuestos. La terapia de combinación con otros agente cardiovasculares es también reivindicada.
EC2004005368A 2002-04-16 2004-10-15 "antagonistas de los receptores de trombina" ECSP045368A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16

Publications (1)

Publication Number Publication Date
ECSP045368A true ECSP045368A (es) 2005-01-03

Family

ID=29250954

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005368A ECSP045368A (es) 2002-04-16 2004-10-15 "antagonistas de los receptores de trombina"

Country Status (34)

Country Link
US (3) US7304078B2 (es)
EP (5) EP2065384B1 (es)
JP (2) JP4558331B2 (es)
KR (1) KR101026929B1 (es)
CN (1) CN1659162B (es)
AR (1) AR039570A1 (es)
AT (3) ATE378330T1 (es)
AU (1) AU2003221932B2 (es)
BR (1) BRPI0309309B8 (es)
CA (1) CA2482858C (es)
CY (3) CY1107184T1 (es)
DE (3) DE60335679D1 (es)
DK (2) DK1495018T3 (es)
EC (1) ECSP045368A (es)
ES (3) ES2338171T3 (es)
FR (1) FR15C0047I2 (es)
HK (3) HK1070887A1 (es)
IL (1) IL164585A (es)
LT (1) LTC1495018I2 (es)
LU (1) LU92759I2 (es)
MX (1) MXPA04010308A (es)
MY (1) MY144040A (es)
NL (1) NL300746I1 (es)
NO (2) NO330500B1 (es)
NZ (2) NZ535880A (es)
PE (1) PE20040412A1 (es)
PL (1) PL214718B1 (es)
PT (2) PT1495018E (es)
RU (2) RU2329264C9 (es)
SG (1) SG164279A1 (es)
SI (2) SI1495018T1 (es)
TW (1) TWI343919B (es)
WO (1) WO2003089428A1 (es)
ZA (1) ZA200408342B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
CA2567981C (en) * 2004-05-28 2010-08-31 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
EP1799243B1 (en) * 2004-10-06 2015-07-15 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
US20060172397A1 (en) * 2005-01-14 2006-08-03 Schering Corporation Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs
CA2594741A1 (en) * 2005-01-14 2006-07-20 Schering Corporation Synthesis of himbacine analogs
EP2196454B1 (en) * 2005-01-14 2014-08-27 Merck Sharp & Dohme Corp. Exo-and diastereo-selective syntheses of himbacine analogs
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
US7772276B2 (en) 2005-01-14 2010-08-10 Schering Corporation Exo-selective synthesis of himbacine analogs
EP1863778B1 (en) * 2005-03-31 2015-12-30 Merck Sharp & Dohme Corp. Spirocyclic thrombin receptor antagonists
US20070219154A1 (en) * 2005-12-20 2007-09-20 Suxing Liu Methods for preventing and/or treating a cell proliferative disorder
EP1971336A2 (en) * 2005-12-22 2008-09-24 Shering Corporation Thrombin receptor antagonists as phophylaxis to complications from cardiopulmonary surgery
TW200812619A (en) * 2006-04-06 2008-03-16 Schering Corp TRA combination therapies
KR20080110880A (ko) 2006-04-13 2008-12-19 쉐링 코포레이션 융합된 환 트롬빈 수용체 길항제
US8022088B2 (en) * 2006-06-29 2011-09-20 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
AU2007320029A1 (en) * 2006-10-04 2008-05-22 Schering Corporation Thrombin receptor antagonists based on the modified tricyclic unit of himbacine
KR20090074219A (ko) * 2006-10-04 2009-07-06 쉐링 코포레이션 트롬빈 수용체 길항제로서의 비사이클릭 및 트리사이클릭 유도체
EP2120879A2 (en) * 2006-12-22 2009-11-25 Schering Corporation Disintegration promoters in solid dose wet granulation formulations
EP2134344A1 (en) * 2007-03-23 2009-12-23 Schering Corporation Reduction of adverse events.after percutaneous intervention by use of a thrombin receptor antagonist
MY152040A (en) 2008-02-05 2014-08-15 Sanofi Aventis Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
CN101981035B (zh) 2008-02-05 2013-08-28 赛诺菲-安万特 作为par1抑制剂的三唑*盐、其制备及其作为药物的用途
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
WO2009143039A2 (en) 2008-05-19 2009-11-26 Schering Corporation Heterocyclic compounds as factor ixa inhibitors
SI2438060T1 (sl) * 2009-06-04 2014-04-30 Merck Sharp & Dohme Corp. Aktivni metabolit trombin receptorskega antagonista
US20120141586A1 (en) 2009-06-08 2012-06-07 Rubi Burlage Thrombin receptor antagonist and clopidogrel fixed dose tablet
US8609676B2 (en) 2009-08-04 2013-12-17 Merck Sharp & Dohme, Corp. 4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors
WO2011128420A1 (de) 2010-04-16 2011-10-20 Sanofi Pyridyl-vinyl-pyrazolo-chinoline als par1-inhibitoren
EP2558465B1 (de) 2010-04-16 2014-12-17 Sanofi Trizyklische pyridyl-vinyl-pyrrole als par1-inhibitoren
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
WO2013134012A1 (en) 2012-03-06 2013-09-12 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
WO2015013083A1 (en) * 2013-07-22 2015-01-29 Merck Sharp & Dohme Corp. Co-crystal of the par-1 receptor antagonist vorapaxar and aspirin
EP3035929A4 (en) 2013-08-22 2017-03-15 Merck Sharp & Dohme Corp. 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
WO2015026685A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
US9808473B2 (en) 2013-08-22 2017-11-07 Merck Sharp & Dohme Corp. Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TW201738221A (zh) * 2016-04-22 2017-11-01 Jiangsu Tasly Diyi Pharmaceutical Co Ltd 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
CN116133660A (zh) 2020-07-22 2023-05-16 詹森药业有限公司 可用作因子XIa抑制剂的化合物
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
ID24726A (id) * 1997-11-25 2000-08-03 Schering Corp Antagonis-antagonis reseptor trombin
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
PE20020235A1 (es) 2000-06-15 2002-04-02 Schering Corp Derivados de nor-seco himbacina como antagonistas de los receptores de trombina
ATE525378T1 (de) 2001-10-18 2011-10-15 Schering Corp Himbacinanaloga als thrombinrezeptorantagonisten

Also Published As

Publication number Publication date
ES2297150T7 (es) 2012-03-16
ES2297150T3 (es) 2008-05-01
SI1495018T1 (sl) 2008-04-30
CA2482858A1 (en) 2003-10-30
NO330500B1 (no) 2011-05-02
EP2065384B1 (en) 2011-01-05
DE60317493T2 (de) 2008-09-18
EP2065384A1 (en) 2009-06-03
JP2010132710A (ja) 2010-06-17
HK1070887A1 (en) 2005-06-30
PL214718B1 (pl) 2013-09-30
PT1495018E (pt) 2008-02-19
KR20040099441A (ko) 2004-11-26
EP1860106B1 (en) 2010-01-20
PL373332A1 (en) 2005-08-22
AU2003221932A1 (en) 2003-11-03
ATE378330T1 (de) 2007-11-15
JP2005528406A (ja) 2005-09-22
EP2062890A1 (en) 2009-05-27
TWI343919B (en) 2011-06-21
EP1982984A3 (en) 2008-10-29
IL164585A (en) 2010-11-30
LTC1495018I2 (lt) 2017-04-10
CY1107184T1 (el) 2012-10-24
DE60335679D1 (de) 2011-02-17
EP1495018B1 (en) 2007-11-14
ATE455774T1 (de) 2010-02-15
PE20040412A1 (es) 2004-07-12
ES2338171T3 (es) 2010-05-04
FR15C0047I2 (fr) 2016-05-06
EP2062890B1 (en) 2011-01-05
PT2065384E (pt) 2011-03-16
HK1123302A1 (en) 2009-06-12
BRPI0309309B1 (pt) 2018-09-04
JP4558331B2 (ja) 2010-10-06
LU92759I2 (en) 2015-08-31
EP1860106A1 (en) 2007-11-28
CY2015029I2 (el) 2016-04-13
NZ535880A (en) 2007-11-30
DK1495018T3 (da) 2008-02-18
ES2357876T3 (es) 2011-05-03
ZA200408342B (en) 2006-05-31
DE60317493D1 (en) 2011-01-13
RU2329264C9 (ru) 2009-04-20
RU2329264C2 (ru) 2008-07-20
US20070179187A1 (en) 2007-08-02
NZ575139A (en) 2010-08-27
EP1982984A2 (en) 2008-10-22
BR0309309A (pt) 2005-02-15
CN1659162A (zh) 2005-08-24
EP1495018A1 (en) 2005-01-12
US7304078B2 (en) 2007-12-04
CY2015029I1 (el) 2016-04-13
CA2482858C (en) 2010-11-30
TW200404068A (en) 2004-03-16
CN1659162B (zh) 2011-08-31
KR101026929B1 (ko) 2011-04-04
RU2004133375A (ru) 2005-07-10
HK1129893A1 (en) 2009-12-11
DK2065384T3 (da) 2011-05-02
SG164279A1 (en) 2010-09-29
WO2003089428A1 (en) 2003-10-30
MXPA04010308A (es) 2005-02-03
FR15C0047I1 (es) 2015-08-28
NO2015016I2 (no) 2015-07-09
AR039570A1 (es) 2005-02-23
US7713999B2 (en) 2010-05-11
NL300746I2 (es) 2016-01-21
ATE494284T1 (de) 2011-01-15
US20030216437A1 (en) 2003-11-20
EP1495018B3 (en) 2011-03-16
EP1982984B1 (en) 2013-02-13
DE60331114D1 (de) 2010-03-11
AU2003221932B2 (en) 2007-11-22
US20070270439A1 (en) 2007-11-22
NO20044963L (no) 2004-11-15
MY144040A (en) 2011-07-29
NO2015016I1 (no) 2015-07-20
NL300746I1 (es) 2016-01-21
BRPI0309309B8 (pt) 2021-05-25
IL164585A0 (en) 2005-12-18
DE60317493T3 (de) 2018-07-12
RU2008106401A (ru) 2009-08-27
SI2065384T1 (sl) 2011-05-31
CY1111363T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
ECSP045368A (es) "antagonistas de los receptores de trombina"
CO5570668A2 (es) Derivados triciclicos sustituidos de himbacina que son antagonistas del receptor de trombina y composiciones farmaceuticas que los contienen
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
AR049696A1 (es) Derivados de indol
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20090441A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
AR056883A1 (es) Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3
MX2009003761A (es) Derivados biciclicos y triciclicos como antagonistas del receptor de trombina.
AR074596A1 (es) Derivados de (3-oxo) piridazin-4-ilurea
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
AR036044A1 (es) Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma
DE60303381D1 (de) Neue indolylpiperidin-derivate als potente antihistaminische und antiallergische mittel
AR044543A1 (es) Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa
AR035320A1 (es) Compuestos activadores de hppardelta, composicion farmaceutica, su uso en la preparacion de medicamentos, metodo para el tratamiento de enfermedades mediadas por hppardelta
TW200626584A (en) Thrombin receptor antagonists
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR044011A1 (es) Antagonistas de mchr1 heterociclicos
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
AR051334A1 (es) Derivados de 2- amido-4-feniltiazol
AR017189A1 (es) Antagonistas del receptor de trombina triciclico sustituido, composicion farmaceutica que lo contiene y su uso para la manufactura de un medicamento
CO5590916A2 (es) Dicetopiperacinas sustituidas como antagonistas de oxitocina
AR063095A1 (es) Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina
AR035605A1 (es) Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
AR052332A1 (es) Derivados de benzdioxanpiperazina con una afinidad combinada para receptores de dopamina-d2 y sitios de reabsorcion de serotonina, composiciones farmaceuticas que los contienen y su empleo como medicamentos para el tratamiento de enfermedades del snc